1.4396 -0.94 (-39.51%) | 11-29 11:14 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 2.18 ![]() |
1-year : | 3.46 ![]() |
Resists | First : | 1.87 ![]() |
Second : | 2.97 ![]() |
Pivot price | 0.37 ![]() |
|||
Supports | First : | 0.1 ![]() |
Second : | 0.08 ![]() |
MAs | MA(5) : | 0.84 ![]() |
MA(20) : | 0.32 ![]() |
MA(100) : | 0.74 ![]() |
MA(250) : | 0.81 ![]() |
|
MACD | MACD : | 0.2 ![]() |
Signal : | 0 ![]() |
%K %D | K(14,3) : | 43.3 ![]() |
D(3) : | 38.2 ![]() |
RSI | RSI(14): 67.1 ![]() |
|||
52-week | High : | 2.97 | Low : | 0.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SEEL ] has closed below upper band by 7.2%. Bollinger Bands are 452.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 2.97 - 2.99 | 2.99 - 3 |
Low: | 2.21 - 2.22 | 2.22 - 2.23 |
Close: | 2.36 - 2.38 | 2.38 - 2.4 |
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Wed, 29 Nov 2023
Why Workday Shares Are Trading Higher By Around 9%; Here Are ... - Investing.com UK
Wed, 29 Nov 2023
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering - BioSpace
Tue, 28 Nov 2023
Seelos Therapeutics Announces Pricing of $5.55 Million Public ... - PR Newswire
Tue, 28 Nov 2023
Seelos Therapeutics Announces Proposed Public Offering - Investing News Network
Tue, 28 Nov 2023
Seelos Therapeutics commences a public offering of its shares (NASDAQ:SEEL) - Seeking Alpha
Tue, 28 Nov 2023
Healthcare Stocks Making Moves Tuesday: RDHL, ICCM, GYRE, CDIO, AXLA, CABA, BDRX, SEEL - InvestorsObserver
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 161 (M) |
Held by Insiders | 1.4615e+008 (%) |
Held by Institutions | 2.8 (%) |
Shares Short | 10,230 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -3 % |
Return on Assets (ttm) | 104.1 % |
Return on Equity (ttm) | -135.8 % |
Qtrly Rev. Growth | 1.55e+006 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -0.5 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -35 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | -17.7 |
Dividend | 0 |
Forward Dividend | 8.32e+006 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |